3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
13
OTHER
5
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
1019
Carboplatin
959
Paclitaxel
932
Gemcitabine
793
Cisplatin
748
Docetaxel
682
Bevacizumab
610
Pemetrexed
502
Nivolumab
486
Cyclophosphamide
466
Capecitabine
461
Fluorouracil
417
Dexamethasone
402
Rituximab
372
Oxaliplatin
347
Injections
342
atezolizumab
297
Trastuzumab
297
Leucovorin
286
Cetuximab
282
Irinotecan
266
130-nm albumin-bound paclitaxel
252
Prednisone
244
Doxorubicin
240
Ipilimumab
226
Lenalidomide
220
Fulvestrant
217
fludarabine
214
durvalumab
205
Erlotinib Hydrochloride
188
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Interventional
×
Interleukin-12
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled